Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
Lupin's R&D teams are working on products with a near-zero global warming potential propellant
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
Company receives acceptability, in principle, for ZyVac TCV making it eligible for purchase by United Nations procurement agencies
ActivShield technology is a portable, novel sterilization modality that does not require conventional infrastructure
This partnership will enable healthcare organizations to provide best-in-class patient/consumer experiences
Product basket comprises 2,047 medicines and 300 surgical devices covering all major therapeutic groups
Subscribe To Our Newsletter & Stay Updated